Haemodynamic derangement in human immunodeficiency virus-infected patients with hepatitis C virus-related cirrhosis: The role of bacterial translocation

Liver International

Volumn 31, Issue 6, 2011, Pages 850-858

  Montes de Oca, Monserrat ^a   Blanco, Maria Jose ^a   Marquez, Mercedes ^a   Soto, Maria Jose ^a   Fernandez Gutiérrez, Clotilde ^a   Rodriguez Ramos, Claudio ^a   Giron Gonzalez, Jose A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Cirrhosis; Haemodynamic alterations; HCV infection; HIV infection; Interleukin 6; Intestinal permeability; Macrophage activation

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALDOSTERONE; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTERLEUKIN 6; LAMIVUDINE PLUS ZIDOVUDINE; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROTEINASE INHIBITOR; QUINOLONE DERIVATIVE; RENIN; RITONAVIR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; BLOOD SAMPLING; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HEART INDEX; HEMODYNAMICS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE MUCOSA PERMEABILITY; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PLASMA RENIN ACTIVITY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SYSTEMIC VASCULAR RESISTANCE; VIRUS LOAD;

EID: 79958064383     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02505.x     Document Type: Article

References (33)

1. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
2. Porcel A, Díaz F, Rendón P, et al. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162: 323-8.
3. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
4. Huo TI, Lin HC, Huo SC, et al. Comparison of four models for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl 2008; 14: 837-44.
5. Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 32-7.
6. Schumann RR, Latz E. Lipopolysaccharide-binding protein. Chem Immunol 2000; 74: 42-60.
7. Albillos A, de la Hera A, González M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune andhemodynamic derangement. Hepatology 2003; 37: 208-17.
8. Albillos A, de-la-Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004; 363: 1608-10.
9. Genesca J, Gonzalez A, Segura R, et al. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis. Am J Gastroenterol 1999; 94: 169-77.
10. Navasa M, Follo A, Filella X, et al. Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology 1998; 27: 1227-32.
11. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77: 11708-17.
12. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-71.
13. Giorgi J, Hultin L, McKeating J, et al. Shorter survival in advanced HIV-1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-70.
14. Paiardini M, Frank I, Pandrea I, Apetrei C, Silvestri G. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev 2008; 10: 36-46.
15. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135: 226-33.
16. Lozano F, Polo R, GESIDA and National AIDS Plan expert committee, et al. Recommendations from the GESIDA/Spanish AIDS plan regarding antirretroviral treatment in adults with human immunodeficiency virus infection (update Febrery 2009). Enferm Infecc Microbiol Clin 2009; 27: 225-34.
17. Rocktroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82-8.
18. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
20. Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med 2002; 21: 1023-2.
21. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
22. Biggins SW, Kim WR, Terrault NA, Saab S, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-60.
23. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167-76.
24. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-21.
25. Taourel P, Blanc P, Dauzat M, et al. Doppler study of mesenteric, hepatic, and portal circulation in alcoholic cirrhosis: relationship between quantitative Doppler measurements and the severity of portal hypertension and hepatic failure. Hepatology 1998; 28: 932-6.
26. Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 1990; 172: 599-607.
27. Pineda JA, Romero-Gómez M, Díaz-García F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779-89.
28. Girón-González JA, Brun F, Terrón A, Vergara A, Arizcorreta A. Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study. Antiviral Ther 2007; 12: 899-907.
29. Márquez M, Fernández-Gutiérrez C, Montes-de-Oca M, et al. Chronic antigenic stimuli as a possible explanation for the immunodepression caused by liver cirrhosis. Clin Exp Immunol 2009; 158: 219-29.
30. Ubeda M, Muñoz L, Borrero MJ, et al. Critical role of the liver in the induction of systemic inflammation in rats with compensated cirrhosis. Hepatology 2010; 52: 2086-95.
31. Wang JJ, Gao GW, Gao RZ, et al. Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension. World J Gastroenterol 2004; 10: 689-93.
32. Girón-González JA, Martínez-Sierra C, Rodriguez-Ramos C, et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int 2004; 24: 437-45.
33. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology 2010; 51: 1445-9.